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A B S T R A C T   
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with 
pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pul-
monary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with 
pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical 
practice. 
Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study 
of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or 
until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious 
adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System 
Organ Classes version 21.0, collected during routine clinic visits (usually every 3–6 months) and collated via case 
report forms. 
Results: In total, 326 patients with PAH were included in the analysis. The most common AEs in these patients 
were dizziness (11.7%), right ventricular (RV)/cardiac failure (10.7%), edema/peripheral edema (10.7%), 
diarrhea (8.6%), dyspnea (8.0%), and cough (7.7%). The most common SAEs were RV/cardiac failure (10.1%), 
pneumonia (6.1%), dyspnea (4.0%), and syncope (3.4%). The exposure-adjusted rate of hemoptysis/pulmonary 
hemorrhage was 2.5 events per 100 patient-years. 
Conclusion: Final data from EXPERT show that in patients with PAH, the safety of riociguat in clinical practice 
was consistent with clinical trials, with no new safety concerns identified and a lower exposure-adjusted rate of 
hemoptysis/pulmonary hemorrhage than in the long-term extension of the Phase 3 trial in PAH.   
1. Introduction 
Pulmonary arterial hypertension (PAH) is a form of pulmonary hy-
pertension (PH) characterized by increased pulmonary vascular resis-
tance (PVR) due to progressive remodeling of the pulmonary 
vasculature and can ultimately lead to death due to right heart failure 
[1–3]. PAH is characterized hemodynamically by precapillary PH, 
defined most recently [3] by a mean pulmonary arterial pressure ≥ 20 
mmHg (previously ≥ 25 mmHg) [4], a pulmonary artery wedge pres-
sure ≤ 15 mmHg and PVR ≥ 3 Wood units in the absence of other causes 
of precapillary PH such as PH due to lung diseases, chronic thrombo-
embolic pulmonary hypertension (CTEPH), or other rare diseases [4]. 
Approved targeted therapies for PAH include prostacyclin analogs, a 
prostacyclin receptor agonist, endothelin receptor antagonists (ERAs), 
phosphodiesterase type 5 inhibitors (PDE5i), and the soluble guanylate 
cyclase stimulator, riociguat [4,5]; calcium channel blockers are also 
occasionally used for treatment of selected patients with PAH [4], 
although they are not generally described as PH-targeted drugs. Rioci-
guat is approved for the treatment of adults with PAH and inoperable or 
persistent/recurrent CTEPH [6,7] based on robust efficacy and safety 
data from two Phase 3, randomized, placebo-controlled trials–Pulmo-
nary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator 
Trial-1 (PATENT-1) [8] and Chronic Thromboembolic Pulmonary Hy-
pertension Soluble Guanylate Cyclase–Stimulator Trial-1 (CHEST-1) [9], 
respectively–and their long-term extension studies PATENT-2 [10,11] 
and CHEST-2 [12,13]. 
EXPosurE Registry RiociguaT in patients with PH (EXPERT) was a 
prospective, non-interventional registry to monitor the long-term safety 
of riociguat in clinical practice. 
2. Methods 
2.1. Study design 
EXPERT (NCT02092818) was an international, multicenter, pro-
spective, uncontrolled, non-interventional cohort study of patients 
treated with riociguat in 28 countries (see supplement for list). EXPERT 
was linked with the Comparative, Prospective Registry of Newly Initi-
ated Therapies for Pulmonary Hypertension (COMPERA [https://com 
pera.org/], one of the largest global academic PH registries. This was 
consistent with guidance from regulatory authorities to utilize existing 
registries. 
Patients were followed for 1–4 years from enrollment (including 
post-treatment follow-up for safety events) during a recruitment period 
of 3 years or until 30 days after stopping riociguat treatment. Data were 
collected using a case report form (CRF) based on the COMPERA CRF 
extended to obtain riociguat safety data. Results were collected during 
routine clinical follow-up visits, usually every 3–6 months. EXPERT ran 
from May 2014 (first patient, first visit) to March 2018 (last patient, last 
visit) and was conducted in accordance with good pharmacovigilance 
practices. Protocol approvals from independent ethics committees or 
institutional review boards at all participating centers were obtained. 
EXPERT was not requested but was accepted by the European Medicines 
Agency for the collection of additional long-term post-approval data on 
riociguat. 
2.2. Patients 
Patients with PH who started treatment or were already being 
treated with riociguat were eligible for inclusion. Patients participating 
in an interventional clinical trial were excluded. The protocol asked for 
the indications (PAH and CTEPH) for riociguat to be considered; how-
ever, 48 patients with PH in Groups 2, 3, or 5 of the international 
classification of PH [14] (for which riociguat is not licensed [“other 
PH”]) were enrolled. 
Patients with disease duration ≥6 months were defined as prevalent, 
and those diagnosed within <6 months of enrollment were defined as 
incident. Patients were defined as riociguat-pretreated if they had been 
receiving riociguat for ≥3 months before registry entry and as riociguat- 
newly treated if they had been receiving riociguat for <3 months before 
registry entry. Riociguat-newly treated patients were therefore not 
necessarily incident patients and could have received PAH-approved 
therapy before riociguat. Newly treated patients were further catego-
rized as switched or non-switched. Switched patients were newly treated 
patients who had stopped prior therapy ≤10 days before commencing 
riociguat. 
2.3. Data collection 
The following data were collected at baseline: demographics, medi-
cal history, comorbidities, adverse events (AEs), disease history, preg-
nancy, history of smoking, 6-min walking distance (6MWD), World 
Health Organization functional class (WHO FC), Borg Dyspnea Index, 
EuroQoL 5-dimensional Visual Analog Score (EQ-5D VAS), hemody-
namic parameters from right heart catheterization, biomarkers (N-ter-
minal prohormone of brain natriuretic peptide and brain natriuretic 
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peptide), laboratory variables, riociguat dose, and prior or concomitant 
PAH-approved therapy. PH etiology was collected according to the Dana 
Point Classification 2008 [15] but is shown in this report in terms of the 
Nice Classification, 2013 [14]. The following were documented at each 
follow-up visit: AEs; changes in treatment; changes of demographics, 
pregnancy, and smoking status; 6MWD; WHO FC; Borg Dyspnea Index; 
EQ-5D VAS; hemodynamic parameters; biomarkers; laboratory vari-
ables; and riociguat dose. 
2.4. Safety assessments 
The primary safety outcomes were AEs and serious adverse events 
(SAEs) coded using Medical Dictionary for Regulatory Activities (Med-
DRA) preferred terms and System Organ Classes version 21.0. An AE was 
considered serious if it: resulted in death, was life-threatening, required 
inpatient hospitalization or prolongation of hospitalization (with spe-
cific exceptions, defined in the protocol), resulted in persistent or sig-
nificant disability or incapacity, was a congenital abnormality or birth 
defect, or was medically important. Secondary safety outcomes included 
AEs and SAEs of special interest (hypotension and hemoptysis/pulmo-
nary hemorrhage). The outcomes of all AEs and SAEs were followed up 
and documented. Where required, study staff contacted the investigators 
to obtain further information. This report focuses on AEs and SAEs 
occurring during the treatment phase (onset date ≤ 2 days after the most 
recent dose of riociguat). Deaths were analyzed in terms of all SAEs with 
a fatal outcome with onset during the treatment phase and the post- 
treatment phase (onset date > 2 days after discontinuation until the 
end of the 30-day safety follow-up). 
2.5. Statistical methods and populations analyzed 
Planned enrollment for the entire study was 900 patients. This 
allowed for the detection of ≥3 “uncommon” AEs with an incidence 
≥0.5%. EXPERT was an observational study. All variables and out-
comes, including comparisons between predefined groups (such as 
newly treated versus pretreated patients, and prevalent versus incident 
patients) were analyzed descriptively. Statistical analyses of these 
comparisons were not performed because they would be of limited value 
without adjustment for differences between the groups. All analyses 
were performed with SAS 9.3. Categorical variables were analyzed using 
frequency tables and continuous variables by summary statistics (mean 
± standard deviation [SD], median, and minimum–maximum range). 
Survival rates were estimated from Kaplan− Meier plots. The evaluable 
population consisted of all enrolled patients who did not withdraw 
consent and had received at least one dose of riociguat with dosing data 
available. 
3. Results 
3.1. Types of PH enrolled 
The entire evaluable population consisted of 1330 patients: 326 with 
PAH, 956 with CTEPH, and 48 with “other PH.” The EXPERT study 
therefore exceeded its planned enrollment by over 400 patients. In view 
of the differences between PAH and CTEPH in pathophysiology, treat-
ment, and outcomes, it was decided to analyze and present results 
separately for the two conditions. This report concentrates on patients 
with PAH with results in CTEPH described in a separate publication 
[29]. Results for the patients with “other PH” are not discussed further as 
riociguat is not indicated for these patients, the sample size was too 
small to permit conclusions, and the characteristics of this patient group 
varied widely due to the mix of PH entities. 
3.2. PAH patient disposition 
The evaluable population with PAH consisted of 326 patients: 182 
(55.8%) riociguat-pretreated and 144 (44.2%) riociguat-newly treated. 
Approximately 87% of patients completed the study (Fig. 1). 
3.3. Demographics and baseline characteristics 
The mean age of the patients was 54.0 ± 16.5 years, with a median 
interquartile range (IQR) disease duration of 3.4 (0.8–6.7) years; 234 
patients (71.8%) were women. PAH was prevalent in 254 patients 
(77.9%), incident in 61 (18.7%), and unknown in 11 (3.4%). At baseline, 
riociguat was used in combination with ERAs alone in 183 patients 
(56.1% [bosentan, 23.3%; macitentan, 22.1%; ambrisentan, 10.7%]), 
with prostanoids alone in 12 (3.7% [iloprost, 2.2%; intravenous tre-
prostinil, 1.2%; inhaled epoprostenol, 0.3%]), and with both classes in 
43 (13.2%). No patient received concomitant PDE5i. At Visit 6 (month 
33− <39), 3 years, 86.6% of patients were receiving combination ther-
apy. Approximately 90% of patients had at least one comorbidity. Other 
baseline demographics are shown in Table 1. Most patients (69.3%) had 
idiopathic PAH (Fig. 2). 
3.4. Riociguat safety 
3.4.1. Total population 
The median (range) duration of observation and riociguat treatment 
was 472.5 (0.0–1381.0) days and 467.0 (0.0–1381.0) days, respectively. 
In total, 229 patients with PAH (70.2%) experienced AEs and 152 
(46.6%) experienced SAEs. These events were considered drug-related 
by the investigator in 49 patients (15.0%) and 23 patients (7.1%), 
respectively. The most common AEs and SAEs are shown in Table 2. 
Discontinuation due to AEs and SAEs occurred in 24 (7.4%) and 21 
(6.4%) patients, respectively. The most common AEs leading to 
discontinuation were right ventricular (RV) failure/cardiac failure and 
dyspnea, each in four patients (1.2%), hypotension in three patients 
(0.9%), and hemoptysis in two patients (0.6%). The most common SAEs 
leading to discontinuation were RV failure/cardiac failure and dyspnea, 
each in four patients (1.2%). Safety data for patients according to use of 
riociguat as monotherapy or in combination with other PAH-specific 
Fig. 1. Patient disposition. 
PAH, pulmonary arterial hypertension. The numbers and percentages refer to 
the total PAH population enrolled (n = 331). 
Chart shows primary reason for discontinuation. 
aOther reasons for not completing the study are listed in Supplementary 
Table 1. 
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drugs are shown in Supplementary Table 2. Overall, rates of AEs were 
slightly higher in the three combination therapy subgroups 
(66.7–74.3%) than with riociguat monotherapy (61.4%). 
Hemorrhages were reported in 41 patients (12.6%) and serious 
hemorrhages in 17 patients (5.2%). The most frequently occurring 
hemorrhages were epistaxis in 11 patients (3.4%), hemoptysis in eight 
patients (2.5%), and hemoglobin decreased in six patients (1.8%); pul-
monary hemorrhage was not reported. The most common serious 
hemorrhages were hemoptysis (n = 6; 1.8%), and gastrointestinal 
hemorrhage and hematemesis, each in two patients (0.6%). Of all pa-
tients with hemorrhages, six were recorded as receiving non-vitamin K 
antagonist anticoagulants (NOACs) and 16 as receiving vitamin K an-
tagonists (VKAs). Hemoptysis was considered an AE of special interest 
and is discussed further below. 
3.4.2. Safety in prevalent versus incident patients 
A post hoc analysis compared prevalent patients (disease duration ≥
6 months) (n = 254) with incident PAH patients (diagnosed within <6 
months of enrollment) (n = 61) according to disease duration data 
available at baseline. Disease characteristics, including 6MWD and 
WHO FC, suggested a more severe disease status in incident patients 
compared with prevalent patients (data not shown). Median (range) 
disease duration was 1.4 (0.0–5.1) months in incident patients and 4.6 
(0.5–49.6) years in prevalent patients. AEs were reported in 175 prev-
alent (68.9%) patients and 45 incident patients (73.8%), and SAEs in 
112 (44.1%) and 32 (52.5%), respectively. 
Table 1 
Baseline demographics and disease characteristics (n = 326).  
Characteristic Mean ± SD or number (%) Characteristic Mean ± SD or number (%) 
Age, years 54.0 ± 16.5 Riociguat daily dose at initial study visit, mg 
Age group, years Mean 6.8 ± 1.3 (n = 322) 
<65 236 (72.4) Median (range) 7.5 (1.5–7.5) (n = 322) 
65 to < 75 51 (15.6)  
≥75 39 (12.0)  
BMI, kg/m2 27.0 ± 11.8 Riociguat median daily dose at initial study visit (mg) 
BMI category, kg/m2 ≤2.5 3 (0.9) 
<18.5 13 (4.0) >2.5 to 4.5 32 (9.8) 
18.5 to < 25 137 (42.0) >4.5 to 6 57 (17.5) 
25 to < 30 96 (29.4) >6 to 7.5 230 (70.6) 
≥30 80 (24.5) Missing 4 (1.2) 
Smoking status Concomitant CCB 22 (6.7) 
Never 218 (66.9)  
Former 91 (27.9) Concomitant anticoagulation therapy 
Current 17 (5.2) Oral anticoagulation 161 (49.4) 
Age at initial PH diagnosis, years 48.9 ± 17.2 (n = 316) Vitamin K antagonist 111 (34.0) 
Median (IQR) disease duration, years 3.4 (0.8–6.7) (n = 316) Direct oral anticoagulant 37 (11.3)   
Other oral anticoagulationb 12 (3.7)   
Other anticoagulantb 7 (2.1)       
Concomitant antiplatelet agents 41 (12.6) 
WHO FC, % (I/II/III/IV/unknown) 4.0/33.4/49.4/6.7/6.4 Comorbidity 
BNP, pg/mL (median, range) 150 (5.8–1305) (n = 57) At least one medical history finding 293 (89.9) 
NT-proBNP, pg/mL (median, range) 437 (12–79 080) (n = 132) Arterial hypertension 115 (35.3) 
6MWD, m 386 ± 132 (n = 282) Thyroid disease 80 (24.5) 
6MWD Diabetes mellitus 50 (15.3) 
<320 ma 76 (23.3) Coronary heart disease 47 (14.4) 
≥320 m 206 (63.2) Obstructive sleep apnea 31 (9.5) 
<380 ma 122 (37.4) Venous thromboembolism 25 (7.7) 
≥380 m 160 (49.1) Cancer 20 (6.1) 
Missing 44 (13.5) History of hemoptysis/lung bleeding 8 (2.5) 
EQ-5D VAS 60.0 ± 22.4 (n = 113) Other 250 (76.7) 
Borg Dyspnea Index 4.1 ± 2.4 (n = 252)   
mPAP, mmHg 51.8 ± 14.6 (n = 282)   
PVR, dyn⋅s⋅cm− 5 822 ± 529 (n = 261)   
PAWP, mmHg 10.4 ± 5.3 (n = 270)   
Cardiac index, L/min/m2 2.5 ± 1.2 (n = 245)   
RAP, mmHg 9.3 ± 6.5 (n = 211)   
SvO2 (%) 64.0 ± 11.3 (n = 211)   
6MWD, 6-min walking distance; BMI, body mass index; BNP, brain natriuretic peptide; CCB, calcium channel blocker; EQ-5D VAS, EuroQoL 5-dimensional Visual 
Analog Score; IQR, interquartile range; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PAH, pulmonary 
arterial hypertension; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SD, 
standard deviation; SvO2, saturated venous oxygen; WHO FC, World Health Organization functional class. 
Data are mean ± SD or number (%) unless otherwise stated. 
Results are for all patients with PAH (n = 326) unless otherwise stated. 
a Thresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time indicating good or poor prognosis [16,17]. 
b As indicated by the investigator on the CRF. 
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3.4.3. Comparison between riociguat-pretreated and riociguat-newly 
treated patients 
Compared with riociguat-pretreated patients, riociguat-newly 
treated patients had a shorter disease duration, shorter 6MWD, a 
higher proportion of WHO FC III/IV disease, and a greater proportion of 
incident disease (Table 3). Approximately 90% of patients in both 
groups had at least one comorbidity. Approximately 88% of patients in 
both groups completed the study (Fig. 3). Of the riociguat-newly treated 
patients, 33 (22.9%) had been switched from previous PAH-approved 
therapy, including 31 (21.5%) switched from PDE5i, 4 (2.8%) from a 
prostanoid, and 1 (0.7%) from an ERA (a few patients were switched 
from more than one prior therapy). 
AEs were reported in 122 riociguat-pretreated patients (67.0%) and 
107 riociguat-newly treated patients (74.3%). SAEs were reported in 74 
patients (40.7%) and 78 patients (54.2%), respectively. Numerically 
more AEs and SAEs in riociguat-newly treated patients were considered 
drug-related and led to drug discontinuation than in riociguat- 
pretreated patients (Table 4). Most individual AEs and SAEs were 
numerically more frequent in newly treated patients. The most common 
AEs and SAEs leading to discontinuation are shown in Supplementary 
Table 3. Safety results in switched patients were generally similar to 
those seen in non-switched patients (data not shown). In both riociguat- 
pretreated and riociguat-newly treated patients, there was a slightly 
higher incidence of AEs with combination therapy compared with 
monotherapy (Supplementary Table 4). 
3.5. AEs and SAEs of special interest 
AEs and SAEs of special interest were numerically more frequent in 
riociguat-newly treated than riociguat-pretreated patients (Table 5). Of 
the six patients with serious hemoptysis, three were receiving concom-
itant anticoagulants, two were receiving a concomitant prostanoid, and 
one was receiving concomitant antiplatelet therapy. 
The incidence of hypotension was low across all subgroups (Sup-
plementary Table 5). There were no events of hemoptysis in patients 
receiving combination therapy with riociguat and a prostanoid, with or 
without an ERA. 
3.6. Deaths and fatal SAEs 
Of the 326 patients, 44 (13.5%) (21 riociguat-newly treated [14.6%] 
and 23 riociguat-pretreated [12.6%]) died or experienced an SAE with a 
fatal outcome with onset during the study. These SAEs began during the 
treatment phase in 40 patients (12.3%): 19 riociguat newly-treated pa-
tients (13.2%) and 21 riociguat-pretreated patients (11.5%). Fatal SAEs 
with post-treatment onset occurred in two riociguat-newly treated pa-
tients (1.4%) and two riociguat-pretreated patients (1.1%). The most 
common fatal SAEs overall were RV failure in 9 patients (2.7%); mul-
tiple organ dysfunction syndrome in 3 (0.9%); and respiratory failure, 
PAH, dyspnea, and sudden cardiac death, each in 2 patients (0.6%). In 
10 patients (3.1%), the SAE was death (cause unknown). The death of 
one patient with PAH was considered related to riociguat by the inves-
tigator. This was a case of hemoptysis, which was complicated by con-
current hereditary hemorrhagic telangiectasia and atypical pneumonia. 
Table 2 
Most common AEs and SAEs in the total population (n = 326).  
AEsa n (%) 
Dizziness 38 (11.7) 
Diarrhea 28 (8.6) 
Dyspnea 26 (8.0) 
Cough 25 (7.7) 
RV failure/cardiac failure 35 (10.7)b 
Peripheral edema/edema 35 (10.7)c 
Pneumonia 22 (6.7) 
Nasopharyngitis 19 (5.8) 
SAEsd n (%) 
RV failure/cardiac failure 33 (10.1)e 
Pneumonia 20 (6.1) 
Dyspnea 13 (4.0) 
Syncope 11 (3.4) 
PAHf 11 (3.4) 
PHf 10 (3.1) 
Respiratory tract infection 9 (2.8) 
Death (cause unknown)g 9 (2.8) 
Atrial fibrillation 8 (2.5) 
Acute kidney injury 8 (2.5) 
AE, adverse event; MedDRA, Medical Dictionary for Regulatory 
Activities; PAH, pulmonary arterial hypertension; PH, pulmo-
nary hypertension; RV, right ventricular; SAE, serious adverse 
event; WHO FC, Word Health Organization functional class; 
6MWD, 6-min walking distance. 
Note. Patients with peripheral edema/edema, or RV failure/ 
cardiac failure, could have both events. 
a Preferred-term AEs reported in ≥5% of patients. 
b Including RV failure in 25 patients (7.7%) and cardiac fail-
ure in 10 patients (3.1%). 
c Including edema in 13 patients (4.0%) and peripheral 
edema in 22 patients (6.7%). 
d Preferred-term SAEs reported in ≥2% of patients. 
e Including RV failure in 25 patients (7.7%) and cardiac fail-
ure in 8 patients (2.5%). 
f Preferred term for worsening of condition. 
g Cases with MedDRA preferred term, “Death” under MedDRA 
system organ class, “General Disorders and Administration Site 
Condition” with AE lowest level term, “Unknown cause of 
death.” 
Fig. 2. PAH etiology according to Nice classification 
2013 [14]. 
ALK1, activin receptor-like kinase 1; BMPR2, bone 
morphogenetic protein receptor type II; CHD, 
congenital heart disease; CTD, connective tissue dis-
ease; HIV, human immunodeficiency virus; PAH, 
pulmonary arterial hypertension. 
aCTD includes systemic sclerosis (9.8%), systemic 
lupus erythematosus (1.8%), mixed CTD (0.9%), un-
differentiated CTD (0.9%), other autoimmune rheu-
matic diseases (0.9%), and overlap (fulfilling two 
criteria) 0.3%.   
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Table 3 
Baseline demographics and disease characteristics in riociguat-pretreated and riociguat-newly treated patients.   
Riociguat-pretreateda (n = 182) Riociguat-newly treatedb (n = 144) 
Age, years 52.9 ± 15.7 55.4 ± 17.4 
Age group, years, n (%) 
<65 138 (75.8) 98 (68.1) 
65 to < 75 31 (17.0) 20 (13.9) 
≥75 13 (7.1) 26 (18.1) 
Female sex, n (%) 132 (72.5) 102 (70.8) 
BMI, kg/m2 27.9 ± 15.0 25.9 ± 5.3 
BMI category, kg/m2, n (%) 
<18.5 5 (2.7) 8 (5.6) 
18.5 to < 25 78 (42.9) 59 (41.0) 
25 to < 30 51 (28.0) 45 (31.3) 
≥30 48 (26.4) 32 (22.2) 
Smoking status, n (%) 
Never 127 (69.8) 91 (63.2) 
Former 49 (26.9) 42 (29.2) 
Current 6 (3.3) 11 (7.6) 
Prevalent (disease duration ≥ 6 months), n (%) 170 (93.4) 84 (58.3) 
Incident (disease duration < 6 months), n (%) 8 (4.4) 53 (36.8) 
Duration status unknown, n (%) 4 (2.2) 7 (4.9) 
Age at initial PH diagnosis, years 47.2 ± 16.5 (n = 178) 51.0 ± 18.0 (n = 138) 
Median (IQR) PH disease duration, years 4.4 (1.8–7.4) (n = 178) 1.5 (0.2–5.7) (n = 138) 
WHO FC, % (I/II/III/IV/unknown) 3.8/43.4/43.4/5.5/3.8 4.2/20.8/56.9/8.3/9.7 
BNP, pg/mL, median (range) 128 (5.8–497) (n = 34) 362 (12–1305) (n = 23) 
NT-proBNP, pg/mL, median (range) 333 (12–19 936) (n = 76) 590 (45–79 080) (n = 56) 
6MWD, m 402 ± 130 (n = 161) 366 ± 132 (n = 121) 
6MWD, n (%) 
<320 mc 40 (22.0) 36 (25.0) 
≥320 m 121 (66.5) 85 (59.0) 
<380 mc 60 (33.0) 62 (43.1) 
≥380 m 101 (55.5) 59 (41.0) 
Missing 21 (11.5) 23 (16.0) 
EQ-5D VAS 59.0 ± 23.7 (n = 69) 61.6 ± 20.2 (n = 44) 
Borg Dyspnea Index 4.1 ± 2.3 (n = 138) 4.1 ± 2.4 (n = 114) 
mPAP, mmHg 50.6 ± 15.3 (n = 152) 53.1 ± 13.6 (n = 130) 
PVR, dyn⋅s⋅cm− 5 757 ± 546 (n = 137) 894 ± 502 (n = 124) 
PAWP, mmHg 10.8 ± 5.8 (n = 145) 9.9 ± 4.8 (n = 125) 
Cardiac index, L/min/m2 2.6 ± 1.5 (n = 132) 2.4 ± 0.7 (n = 113) 
RAP, mmHg 9.7 ± 7.2 (n = 120) 8.7 ± 5.5 (n = 91) 
SvO2 (%) 65.0 ± 10.5 (n = 113) 62.8 ± 12.1 (n = 98) 
Riociguat daily dose at initial study visit, mg 
Mean 7.0 ± 1.0 6.6 ± 1.5 (n = 140) 
Median (range) 7.5 (1.5–7.5) 7.5 (1.5–7.5) (n = 140) 
Riociguat median daily dose at initial study visit, mg, n (%) 
≤2.5 1 (0.5) 2 (1.4) 
>2.5 to 4.5 11 (6.0) 21 (14.6) 
>4.5 to 6 34 (18.7) 23 (16.0) 
>6 to 7.5 136 (74.7) 94 (65.3) 
Missing 0 (0.0) 4 (2.8) 
PH-approved regimen at initial study visit, n (%) 
Riociguat monotherapyd 39 (21.4) 49 (34.0) 
Riociguat combination therapye,f 143 (78.6) 95 (66.0) 
Riociguat + ERA 113 (62.1) 70 (48.6) 
Riociguat + ambrisentan 26 (14.3) 9 (6.3) 
Riociguat + bosentan 49 (26.9) 27 (18.8) 
Riociguat + macitentan 38 (20.9) 34 (23.6) 
Riociguat + prostanoid 9 (4.9) 3 (2.1) 
Riociguat + inhaled epoprostenol 0 (0.0) 1 (0.7) 
Riociguat + IV treprostinil 3 (1.7) 1 (0.7) 
Riociguat + iloprost 6 (3.3) 1 (0.7) 
Riociguat + ERA + prostanoid 21 (11.5) 22 (15.3) 
Concomitant CCB, n (%) 9 (4.9) 13 (9.0) 
Anticoagulation therapy, n (%) 
Oral anticoagulation 96 (52.7) 65 (45.1) 
Vitamin K antagonist 69 (37.9) 42 (29.2) 
Direct oral anticoagulant 18 (9.9) 19 (13.2) 
Other oral anticoagulationg 10 (5.5) 2 (1.4) 
Other anticoagulantg 4 (2.2) 3 (2.1) 
Antiplatelet agents, n (%) 17 (9.3) 24 (16.7) 
Comorbidity, n (%) 
At least one medical history finding 163 (89.6) 130 (90.3) 
Arterial hypertension 60 (33.0) 55 (38.2) 
Thyroid disease 38 (20.9) 42 (29.2) 
Diabetes mellitus 26 (14.3) 24 (16.7) 
Coronary heart disease 25 (13.7) 22 (15.3) 
(continued on next page) 
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Estimated survival rates in the total PAH population at 1, 2, and 3 years 
were 94.2% (95% CI, 90.9–96.3%), 82.2% (95% CI, 75.5–87.2%), and 
71.0% (95% CI, 60.8–79.0%), respectively. Kaplan− Meier survival 
curves for riociguat-newly treated and riociguat-pretreated patients 
with PAH are shown in Fig. 4. 
In the post hoc analysis assessing patients according to disease 
duration, death during the treatment period was numerically more 
common in prevalent PAH patients (34 patients; 13.4%) than in incident 
PAH patients (3 patients; 4.9%). Two patients in each group (0.8% of 
prevalent patients and 3.3% of incident patients) died during the 30-day 
safety follow-up. 
3.7. Other results 
3.7.1. Efficacy assessments 
Results for indicators of efficacy (6MWD, Borg Dyspnea Index, EQ- 
5D VAS, hemodynamic measurements, and biomarkers) had many 
missing data and varied greatly between patients. Moreover, selection 
bias for repeat efficacy assessments could confound the results. These 
results are therefore not shown or discussed here. 
4. Discussion 
4.1. Safety findings 
EXPERT provided data on the safety and tolerability of riociguat in 
more than 300 patients with PAH in real-world clinical practice. The 
types of AEs observed were consistent with those reported in PATENT-1 
[8] and PATENT-2 [10,11], with no new safety signals identified. The 
most common events (e.g., peripheral edema/edema, dizziness, hypo-
tension, RV failure/cardiac failure, dyspnea) were consistent with 
symptoms of the underlying disease or with vasodilatation by riociguat. 
Concomitant anticoagulants, antiplatelet therapy, or prostanoids (which 
have antiplatelet actions) may have contributed to bleeding AEs in some 
patients. The exposure-adjusted rates of hypotension and hemoptysis/-
pulmonary hemorrhage were lower than those reported in PATENT-2 
(6.2 and 5.5 events, respectively, per 100 patient-years) [10]. Most 
patients were receiving combination therapy, mainly with ERAs. In 
patients receiving riociguat as part of a combination regimen, the 
overall incidence of AEs was slightly higher than in patients receiving 
monotherapy. AEs considered drug-related by the investigator were 
more common with riociguat monotherapy than with combination 
Table 3 (continued )  
Riociguat-pretreateda (n = 182) Riociguat-newly treatedb (n = 144) 
Obstructive sleep apnea 19 (10.4) 12 (8.3) 
Venous thromboembolism 14 (7.7) 11 (7.6) 
Cancer 7 (3.8) 13 (9.0) 
History of hemoptysis/lung bleeding 5 (2.7) 3 (2.1) 
Other 142 (78.0) 108 (75.0) 
6MWD, 6-min walking distance; BMI, body mass index; BNP, brain natriuretic peptide; CCB, calcium channel blocker; EQ-5D VAS, EuroQoL 5- 
dimensional Visual Analog Score; ERA, endothelin receptor antagonist; IQR, interquartile range; IV, intravenous; mPAP, mean pulmonary artery 
pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge 
pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SD, standard deviation; SvO2, saturated 
venous oxygen; WHO FC, World Health Organization functional class. 
Data are mean ± SD unless otherwise stated. 
a Receiving riociguat for ≥3 months before entry (n = 182 unless otherwise stated). 
b Receiving riociguat for <3 months before entry (n = 144 unless otherwise stated). 
c Thresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time indicating good or poor prognosis [16,17]. 
d Patients receiving riociguat but no ERA or prostanoid. 
e Patients receiving riociguat + ERA, prostanoid, or both. 
f No patient received concomitant PDE5i during the study. 
g As indicated by the investigator on the CRF. 
Fig. 3. Disposition of riociguat-pretreated and riociguat-newly treated patients with PAH. 
Chart shows primary reason for discontinuation. 
aOther reasons for not completing the study are listed in Supplementary Table 1. 
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therapy, which may be because it is easier to link an AE to treatment if 
the patient is receiving only one drug. These data should be interpreted 
with caution as they are descriptive, they are not adjusted for differences 
between the combination and monotherapy groups, they refer to treat-
ment at baseline, and the number of patients receiving riociguat plus a 
prostanoid as dual therapy was very small. Overall, however, the results 
indicate the safety of riociguat as monotherapy and in combination 
regimens (co-administration with PDE5i is contraindicated and was not 
observed in EXPERT). 
Clinical experience with riociguat shows an increased frequency of 
some AEs such as hypotension, dizziness, and edema during dose 
adjustment [6,7]. These effects, described in the reference safety infor-
mation for the drug, have been attributed to the vasodilatory properties 
of riociguat [6]. In EXPERT, as expected, numerically more 
riociguat-newly treated patients than riociguat-pretreated patients 
experienced AEs and discontinued treatment because of AEs or SAEs. 
These observations may be partly explained by a worse disease state, as 
indicated by baseline 6MWD and WHO FC, but also partly by more 
frequent measurements (e.g., of blood pressure) in the newly treated 
group. For riociguat-pretreated patients, bias may be introduced, 
because those who had to discontinue the drug because of AEs, or who 
died, could not be documented in the study. 
Several registries, including the French PAH registry [18] and 
REVEAL [19], have reported better survival in prevalent than in incident 
PAH cohorts. It has been suggested that prevalent cohorts are enriched 
with patients with better RV function or a better response to therapy or 
that many higher-risk patients do not survive long enough to be enrolled 
as previously diagnosed patients [18–20]. In our post hoc analysis, 
however, rates of AEs and SAEs were similar between prevalent and 
incident patients, indicating that the higher proportion of incident pa-
tients in the riociguat-newly treated group than in the 
riociguat-pretreated group did not disadvantage them in terms of safety. 
There is no explanation for the greater number of deaths in prevalent 
patients than incident patients but it may be related to the longer PAH 
disease duration in the prevalent group. 
Table 4 
Safety summary in riociguat-pretreated and riociguat-newly treated patients.   
Riociguat-pretreateda 
(n = 182) 
Riociguat-newly treatedb  
(n = 144) 
Any AE 122 (67.0) 107 (74.3) 
Most common AEsc 
Dizziness 18 (9.9) 20 (13.9) 
Diarrhea 19 (10.4) 9 (6.3) 
Peripheral edema/edema 19 (10.4)d 16 (11.1)e 
Cough 15 (8.2) 10 (6.9) 
RV failure/cardiac failure 19 (10.4)f 16 (11.1)g 
Dyspnea 13 (7.1) 13 (9.0) 
Nasopharyngitis 13 (7.1) 6 (4.2) 
Pneumonia 10 (5.5) 12 (8.3) 
Fatigue 7 (3.8) 8 (5.6) 
Hypokalemia 6 (3.3) 8 (5.6) 
Nausea 6 (3.3) 8 (5.6) 
Chest discomfort 5 (2.7) 8 (5.6) 
Hypotension 2 (1.1) 11 (7.6) 
Any drug-related AEh 13 (7.1) 36 (25.0) 
Discontinuation due to AE 4 (2.2) 20 (13.9) 
Any SAE 74 (40.7) 78 (54.2) 
Most common SAEsi 
RV failure/cardiac failure 19 (10.4)j 14 (9.7)k 
Pneumonia 9 (4.9) 11 (7.6) 
PAHl 7 (3.8) 4 (2.8) 
PHl 6 (3.3) 4 (2.8) 
Death (cause unknown)m 6 (3.3) 3 (2.1) 
Dyspnea 5 (2.7) 8 (5.6) 
Syncope 5 (2.7) 6 (4.2) 
Respiratory tract infection 5 (2.7) 4 (2.8) 
Acute kidney injury 5 (2.7) 3 (2.1) 
Anemia 4 (2.2) 1 (0.7) 
Ascites 4 (2.2) 0 (0.0) 
Atrial fibrillation 3 (1.6) 5 (3.5) 
Hemoptysis 3 (1.6) 3 (2.1) 
Hypotension 0 (0.0) 5 (3.5) 
Hypoxia 0 (0.0) 3 (2.1) 
Lung infection 0 (0.0) 3 (2.1) 
Oxygen therapy 0 (0.0) 3 (2.1) 
Any drug-related SAEh 5 (2.7) 18 (12.5) 
Discontinuation due to SAE 4 (2.2) 17 (11.8) 
All data are n (%). AE, adverse event; MedDRA, Medical Dictionary for Regu-
latory Activities; PAH, pulmonary arterial hypertension; PH, pulmonary hy-
pertension; RV, right ventricular; SAE, serious adverse event. 
Note. Patients with peripheral edema/edema, or RV failure/cardiac failure, 
could have both events. 
a Receiving riociguat for ≥3 months before entry. Median (range) duration of 
observation and riociguat treatment (days): 472.5 (0.0–1373.0); 467.0 
(0.0–1373.0). 
b Receiving riociguat for <3 months before entry. Median (range) duration of 
observation and riociguat treatment (days): 472.5 (0.0–1381.0); 464.0 
(0.0–1381.0). 
c Preferred-term AEs reported in ≥5% of patients in either group. 
d Including edema in 3 patients (1.6%) and peripheral edema in 16 patients 
(8.8%). 
e Including edema in 10 patients (6.9%) and peripheral edema in 6 patients 
(4.2%). 
f Including RV failure in 15 patients (8.2%) and cardiac failure in 4 patients 
(2.2%). 
g Including RV failure in 10 patients (6.9%) and cardiac failure in 6 patients 
(4.2%). 
h Investigator’s causality assessment. 
i Preferred-term SAEs reported in ≥2% of patients in either group. 
j Including RV failure in 15 patients (8.2%) and cardiac failure in 4 patients 
(2.2%). 
k Including RV failure in 10 patients (6.9%) and cardiac failure in 4 patients 
(2.8%). 
l Preferred term for worsening of condition. 
m Cases with MedDRA preferred term, “Death” under MedDRA system organ 
class, “General Disorders and Administration Site Condition” with adverse event 
lowest level term, “Unknown cause of death”. 
Table 5 
AEs and SAEs of special interest.   
All PAH  
(n = 326)a 
Riociguat- 
pretreatedb (n = 182) 
Riociguat-newly 
treatedc (n = 144) 
Absolute AE rates, n (%) 
Hypotension 13 (4.0) 2 (1.1) 11 (7.6) 
Hemoptysis 8 (2.5) 4 (2.2) 4 (2.8) 
Exposure-adjusted AE rates (95% CI)d 
Hypotension 2.7 (1.5–4.5) 0.7 (0.1–2.2) 5.8 (3.0–9.9) 
Hemoptysis 2.5 (1.4–4.2) 2.1 (0.8–4.3) 3.2 (1.3–6.4) 
Absolute SAE rates, n (%) 
Hypotension 5 (1.5) 0 (0.0) 5 (3.5) 
Hemoptysis 6 (1.8) 3 (1.6) 3 (2.1) 
Exposure-adjusted SAE rates (95% CI)d 
Hypotension 1.1 (0.4–2.3) 0 (0.0–0.0) 2.6 (0.9–5.7) 
Hemoptysis 1.7 (0.8–3.1) 1.4 (0.4–3.3) 2.1 (0.7–4.9) 
AE, adverse event; CI, confidence interval; PAH, pulmonary arterial hyperten-
sion; SAE, serious adverse event. 
Note. Pulmonary hemorrhage was not reported in any patient. 
a Median (range) duration of observation and riociguat treatment (days): 
472.5 (0.0–1381.0); 467.0 (0.0–1381.0). 
b Receiving riociguat for ≥3 months before entry. Median (range) duration of 
observation and riociguat treatment (days): 472.5 (0.0–1373.0); 467.0 
(0.0–1373.0). 
c Receiving riociguat for <3 months before entry. Median (range) duration of 
observation and riociguat treatment (days): 472.5 (0.0–1381.0); 464.0 
(0.0–1381.0). 
d Rates per 100 patient-years, calculated by the number of events divided by 
(total drug exposure in years/100). 
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4.2. Comparison with other studies 
The demographics and disease characteristics of patients with PAH 
in EXPERT were similar to those seen in the REVEAL registry overall 
[21] and the incident group in REVEAL [19]. Patients with PAH in 
EXPERT were approximately 4 years older than in the French National 
Registry [22]. The association of EXPERT with COMPERA, in which 
patients are older than in other registries [23], may have encouraged the 
enrollment of older patients. 
The estimated 1-year survival in patients with PAH in EXPERT was 
comparable to REVEAL (91.0%) [24], the Giessen registry (88.2%) [25], 
the VOLibris post-authorization registry of ambrisentan (91%) [26], a 
large retrospective analysis of US veterans (90.2%) [27], and a low-risk 
population identified in a COMPERA analysis (97.2%) [23]. Survival at 
3 years was also within the range reported elsewhere [25]. 
Registries provide important information about the safety of drugs in 
clinical practice, and thus supplement information gained from selected 
populations under the closely controlled conditions of clinical trials. 
They may also detect previously unsuspected safety signals. Limitations 
inherent in registries including confounding, lack of randomization, 
missing values, and the hazards of generalizing data from the registry 
population to other populations [28], also apply to EXPERT. In addition, 
EXPERT was designed to collect safety information on riociguat; it was 
not designed to provide data on the long-term efficacy of this drug. The 
power analysis for EXPERT was done for the total population. The 
subgroup analysis of PAH patients (n = 326) does not necessarily meet 
the power criteria, and the lower number of patients in subgroup ana-
lyses may result in an under-detection of AEs. 
Strengths of EXPERT include the relatively long observation time 
(median: 473 days) and the large proportion of patients completing the 
study (88%). 
5. Conclusion 
Final data from the EXPERT registry showed that in patients with 
PAH, the long-term safety of riociguat in routine practice was consistent 
with clinical trials, with no new safety concerns identified. 
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gation, Resources, Writing - review & editing, Supervision, Writing - 
original draft, approval of final draft for submission. George Gianna-
koulas: Investigation, Resources, Writing - review & editing, Supervi-
sion, Writing - original draft, approval of final draft for submission. Jens 
Klotsche: Conceptualization, Methodology, Software, Validation, 
Formal analysis, Resources, Evgenia Williams: Validation, Formal 
analysis. Christian Meier: Conceptualization, Methodology, Validation, 
Writing - review & editing, Supervision, Project administration, Funding 
acquisition, Writing - original draft, approval of final draft for submis-
sion. Collaborators. Investigation, Resources, Supervision. Hossein- 
Ardeschir Ghofrani: Conceptualization, Methodology, Investigation, 
Resources, Writing - review & editing, Supervision, Writing - original 
draft, approval of final draft for submission. 
Declaration of competing interest 
The authors declare the following financial interests/personal re-
lationships which may be considered as potential competing interests: 
Prof Marius M. Hoeper reports personal fees from Bayer AG, during the 
conduct of the study; personal fees from Actelion, personal fees from 
Acceleron, personal fees from MSD, personal fees from Jansen, personal 
fees from Pfizer, outside the submitted work. Dr Hans Klose reports 
speaker and consultancy fees from Actelion, Bayer AG, GSK, Novartis, 
Pfizer, and United Therapeutics and research support from Actelion, 
Bayer AG, GSK, Pfizer, and MSD. Dr Michael Halank reports personal 
fees and non-financial support from Actelion, AstraZeneca, Bayer AG, 
Berlin-Chemie, GSK, OMT, MSD, and Novartis. Dr George Giannakoulas 
reports speaker and consultancy fees from Actelion, Bayer AG, ELPEN 
Pharmaceuticals, GSK, Pfizer, Lilly, and United Therapeutics, and 
research support from GSK, ELPEN Pharmaceuticals, and Galenica. Dr 
Henning Gall has received honoraria and/or other support from Acte-
lion, AstraZeneca, Bayer AG, BMS, GSK, Janssen-Cilag, Lilly, MSD, 
Novartis, OMT, Pfizer, and United Therapeutics. Dr Pavel Jansa reports 
consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Prof 
Ekkehard Grünig reports research grants and speaker honoraria/con-
sultancy fees from Actelion and Bayer/MSD, research grants from GSK, 
United Therapeutics, Bellerophon, OMT GmbH, Pfizer, Reata, and 
Novartis, and speaker honoraria from Bial, Medscape, and OrPha Swiss 
GmbH. Prof David Pittrow reports personal fees from Actelion, Bayer 
AG, Aspen, Boehringer Ingelheim, Sanofi, Biogen, Shire, and MSD 
outside the submitted work. Silvia Ulrich reports research grants and 
personal fees from Actelion, Bayer AG, MSD, and Orpha Swiss. Tobias J. 
Lange has received personal fees from Actelion, MSD, Pfizer, and OMT 
Orphan. Dr Iraklis Tsangaris reports speaker and consultancy fees from 
Actelion, Bayer AG, ELPEN Pharmaceuticals, GSK, MSD, Pfizer, and 
United Therapeutics. Stephan Rosenkranz reports remunerations for 
lectures and/or consultancy from Abbott, Actelion, Arena, Bayer AG, 
Ferrer, GSK, MSD, Novartis, Pfizer, and United Therapeutics; and 
research support to his institution from Actelion, Bayer AG, Novartis, 
Pfizer, and United Therapeutics. Repke J. Snijder reports grants from 
Pfizer and Actelion Pharmaceuticals. Prof Iveta Šimková reports con-
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[4] N. Galiè, et al., ESC/ERS guidelines for the diagnosis and treatment of pulmonary 
hypertension: the joint task force for the diagnosis and treatment of pulmonary 
hypertension of the European Society of Cardiology (ESC) and the European 
Respiratory Society (ERS): Endorsed by: Association for European Paediatric and 
Congenital Cardiology (AEPC) International Society for Heart and Lung 
Transplantation (ISHLT), Eur. Respir. J. 46 (4) (2015) 903–975. 
[5] M. Humbert, H.A. Ghofrani, The molecular targets of approved treatments for 
pulmonary arterial hypertension, Thorax 71 (1) (2016) 73–83. 
[6] Bayer AG, Adempas (riociguat tablets): EU summary of product characteristics, 
Available from, https://www.ema.europa.eu/en/documents/product-information/ 
adempas-epar-product-information_en.pdf. (Accessed 18 November 2020). 
[7] Bayer AG, Adempas US prescribing information, 2018. Available from, https://la 
beling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf. (Accessed 18 
November 2020). 
[8] H.A. Ghofrani, et al., Riociguat for the treatment of pulmonary arterial 
hypertension, N. Engl. J. Med. 369 (4) (2013) 330–340. 
[9] H.A. Ghofrani, et al., Riociguat for the treatment of chronic thromboembolic 
pulmonary hypertension, N. Engl. J. Med. 369 (4) (2013) 319–329. 
[10] H.A. Ghofrani, et al., Predictors of long-term outcomes in patients treated with 
riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, 
randomised, long-term extension trial, Lancet Respir. Med. 4 (2016) 361–371. 
[11] L.J. Rubin, et al., Riociguat for the treatment of pulmonary arterial hypertension: a 
long-term extension study (PATENT-2), Eur. Respir. J. 45 (5) (2015) 1303–1313. 
[12] G. Simonneau, et al., Predictors of long-term outcomes in patients treated with 
riociguat for chronic thromboembolic pulmonary hypertension: data from the 
CHEST-2 open-label, randomised, long-term extension trial, Lancet Respir. Med. 4 
(5) (2016) 372–380. 
[13] G. Simonneau, et al., Riociguat for the treatment of chronic thromboembolic 
pulmonary hypertension: a long-term extension study (CHEST-2), Eur. Respir. J. 45 
(5) (2015) 1293–1302. 
[14] G. Simonneau, et al., Updated clinical classification of pulmonary hypertension, 
J. Am. Coll. Cardiol. 62 (Suppl 25) (2013) D34–D41. 
[15] G. Simonneau, et al., Updated clinical classification of pulmonary hypertension, 
J. Am. Coll. Cardiol. 54 (1 Suppl) (2009) S43–S54. 
[16] S. Gaine, G. Simonneau, The need to move from 6-minute walk distance to 
outcome trials in pulmonary arterial hypertension, Eur. Respir. Rev. 22 (130) 
(2013) 487–494. 
[17] O. Sitbon, et al., Long-term intravenous epoprostenol infusion in primary 
pulmonary hypertension: prognostic factors and survival, J. Am. Coll. Cardiol. 40 
(4) (2002) 780–788. 
[18] M. Humbert, et al., Survival in incident and prevalent cohorts of patients with 
pulmonary arterial hypertension, Eur. Respir. J. 36 (3) (2010) 549–555. 
[19] H.W. Farber, et al., Five-year outcomes of patients enrolled in the REVEAL registry, 
Chest 148 (4) (2015) 1043–1054. 
[20] D.P. Miller, et al., Survivor bias and risk assessment, Eur. Respir. J. 40 (3) (2012) 
530–532. 
[21] D.B. Badesch, et al., Pulmonary arterial hypertension: baseline characteristics from 
the REVEAL Registry, Chest 137 (2) (2010) 376–387. 
[22] M. Humbert, et al., Pulmonary arterial hypertension in France: results from a 
national registry, Am. J. Respir. Crit. Care Med. 173 (9) (2006) 1023–1030. 
[23] M.M. Hoeper, et al., Mortality in pulmonary arterial hypertension: prediction by 
the 2015 European pulmonary hypertension guidelines risk stratification model, 
Eur. Respir. J. 50 (2) (2017) 1–10. 
[24] R.L. Benza, et al., Predicting survival in pulmonary arterial hypertension: insights 
from the Registry to Evaluate Early and Long-Term Pulmonary Arterial 
Hypertension Disease Management (REVEAL), Circulation 122 (2) (2010) 
164–172. 
[25] H. Gall, et al., The Giessen Pulmonary Hypertension Registry: survival in 
pulmonary hypertension subgroups, J. Heart Lung Transplant. (2017) 
S1053–S2498. 
[26] J.L. Vachiery, et al., Ambrisentan use for pulmonary arterial hypertension in a 
post-authorization drug registry: the VOLibris Tracking Study, J. Heart Lung 
Transplant. 36 (4) (2017) 399–406. 
[27] A.W. Trammell, et al., EXPRESS: mortality in U.S. veterans with pulmonary 
hypertension: a retrospective analysis of survival by subtype and baseline factors, 
Pulm. Circ. (2019), 2045894019825763. 
[28] M.D. McGoon, et al., Pulmonary arterial hypertension: epidemiology and registries, 
J. Am. Coll. Cardiol. 62 (25 Suppl) (2013) D51–D59. 
[29] H.A. Ghofrani, et al., Riociguat treatment in patients with chronic thromboembolic 
pulmonary hypertension: final safety data from the EXPERT registry, Respir. Med. 
(2020). In this issue. 
M.M. Hoeper et al.                                                                                                                                                                                                                             
